Alembic Pharmaceuticals Ltd. Hits Intraday Low Amid Price Pressure on 18 May 2026

Intraday Performance and Price Movement

Throughout the trading session, Alembic Pharmaceuticals Ltd. faced sustained selling pressure, culminating in a day’s low of Rs 728, down 7.23% from its previous close. The stock’s day change registered a significant drop of -7.1%, marking a continuation of its recent downward trend. Over the last two trading days, the stock has declined by approximately -7.3%, signalling persistent weakness in the near term.

Comparatively, the Pharmaceuticals & Biotechnology sector also faced headwinds but Alembic’s performance lagged, underperforming the sector by -6.49% today. This divergence highlights specific pressures on the stock beyond sector-wide factors.

Technical Indicators and Moving Averages

From a technical standpoint, Alembic Pharmaceuticals Ltd. is trading above its 50-day moving average but remains below its 5-day, 20-day, 100-day, and 200-day moving averages. This mixed positioning suggests short-term weakness amid longer-term resistance levels. The daily moving averages indicate a mildly bearish trend, consistent with the stock’s recent price action.

Weekly and monthly technical indicators present a nuanced picture: the Moving Average Convergence Divergence (MACD) is mildly bullish on a weekly basis but bearish monthly, while Bollinger Bands show mild bullishness weekly and mild bearishness monthly. The Relative Strength Index (RSI) offers no clear signal on either timeframe. The KST oscillator and Dow Theory readings are mildly bullish weekly but bearish monthly, reflecting short-term attempts at recovery overshadowed by longer-term downward momentum. On-Balance Volume (OBV) remains bullish on both weekly and monthly charts, indicating that volume trends have not fully aligned with price declines.

Market Context and Broader Indices

The decline in Alembic Pharmaceuticals Ltd. occurred against a backdrop of a broadly negative market mood. The Sensex opened sharply lower by 430.02 points and continued to slide, closing down 530.38 points at 74,277.59, a loss of -1.28%. This places the Sensex just 3.68% above its 52-week low of 71,545.81, underscoring the prevailing bearish sentiment in the broader market.

Technical analysis of the Sensex reveals it is trading below its 50-day moving average, which itself is positioned below the 200-day moving average, a classic bearish configuration signalling sustained downward pressure on the benchmark index. This environment has contributed to the pressure on mid and small-cap stocks, including Alembic Pharmaceuticals Ltd., which is classified as a small-cap stock.

Comparative Performance Over Various Timeframes

Examining Alembic Pharmaceuticals Ltd.’s performance relative to the Sensex over multiple periods highlights the stock’s relative weakness. The stock’s 1-day return of -7.96% starkly contrasts with the Sensex’s -1.30%. Over one week, Alembic declined -8.43% versus the Sensex’s -2.31%, and over one month, the stock fell -7.99% compared to the Sensex’s -5.40%. Even over three months, Alembic’s -6.96% loss is less severe than the Sensex’s -11.32%, but this is amid a longer-term downtrend.

Year-to-date, Alembic Pharmaceuticals Ltd. has declined -14.85%, slightly worse than the Sensex’s -12.86%. Over the past year, the stock’s performance has been notably weaker, with a -20.75% return compared to the Sensex’s -9.81%. Longer-term returns over five and ten years show mixed results, with Alembic underperforming the Sensex over five years (-23.35% vs 47.94%) but outperforming over ten years (26.87% vs 188.89%), reflecting the stock’s volatility and cyclical nature.

Mojo Score and Rating Update

Alembic Pharmaceuticals Ltd. currently holds a Mojo Score of 42.0, categorised under a 'Sell' Mojo Grade as of 25 Nov 2025, a downgrade from its previous 'Hold' rating. This change reflects a reassessment of the stock’s momentum and quality metrics, signalling increased caution. The downgrade aligns with the stock’s recent price weakness and technical signals.

The company operates within the Pharmaceuticals & Biotechnology industry and sector, where competitive pressures and market dynamics continue to influence stock valuations. As a small-cap entity, Alembic is more susceptible to market volatility and sector-specific fluctuations.

Summary of Immediate Pressures

The immediate price pressure on Alembic Pharmaceuticals Ltd. stems from a combination of broader market weakness, sector underperformance, and technical resistance levels. The stock’s inability to sustain levels above key moving averages, coupled with the Sensex’s bearish trend and proximity to 52-week lows, has contributed to today’s intraday low and negative returns.

While volume indicators such as OBV remain bullish on longer timeframes, the daily and weekly price action suggests that sellers currently dominate trading sessions. This dynamic has resulted in the stock’s underperformance relative to both its sector and the benchmark index.

Conclusion

In summary, Alembic Pharmaceuticals Ltd.’s decline to an intraday low of Rs 728 reflects a confluence of market-wide bearishness, sector-specific challenges, and technical headwinds. The stock’s recent downgrade to a 'Sell' Mojo Grade and its underperformance across multiple timeframes underscore the prevailing pressures. Investors monitoring the stock should note the current environment characterised by subdued momentum and price weakness relative to broader indices and sector peers.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →